

From: Cathy Wright <pharma@smiconferences.co.uk>

To: Kester, Tonykester@aging.sc.gov

Date: 10/24/2016 9:53:23 AM

Subject: The Most Prominent Updates in Superbugs Discussed by Pfizer, Janssen, AstraZeneca and US Government Bodies

Superbugs & Superdrugs USA 2016

[Register](#) | [Program](#) | [Attendee List](#)

When: Conference: Nov 14th & 15th | Two Interactive Workshops: Nov 16th

Where: Renaissance Woodbridge Hotel, Iselin, New Jersey

**** Free content **** Access interviews with **BARDA, Pfizer, Janssen** + more! [Read them here](#)

Proudly Sponsored by **Noigel** and **Polyphor**

12+ HRS OF CONTENT ON GROUND BREAKING INNOVATIONS

OVER 17 THOUGHT PROVOKING PRESENTATIONS

3+ HRS OF NETWORKING TO SECURE FUTURE COLLABORATIONS

SPOTLIGHT ON CLINICAL PROGRESS AND INDUSTRY INCENTIVES

KEYNOTES FROM LEADING GOVERNMENT BODIES

3 WEEKS REMAIN

Now at the forefront of capturing the latest developments and breakthroughs against antibiotic resistance, SMi Group's [Superbugs & Superdrugs USA](#) event will arrive to North America in just **3 week's time**. The USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline, resistance prevention, plus much more.

Registration will be closing soon – download the latest brochure and secure your place today at www.superbugs-usa.com

5 KEY SESSIONS AT SUPERBUGS & SUPERDRUGS USA

1. HOST NATION KEYNOTES: Evaluate current progress in the development of the US National Action Plan through host nation keynotes presented by leading government bodies including **PAHO/WHO, NIH and BARDA**. Highlights include updates into PPP investment opportunities and exclusive results following the first of year of the US Government "CARB Initiative".

"BARDA and its interagency partners, specifically the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID) in particular, have demonstrated success in providing direct support to developers of promising products capable of addressing the global threat of AMR that may have otherwise never been developed without support." - BARDA

2. ENABLE DRUG DISCOVERY: Develop clinical assets through strategic partnerships and receive progressive insight on innovative developments in big pharma. Discover **new pathways**, the **microbial metagenomics** approach, and **zoonotic links** between animals and humans to target emerging infectious diseases.

"Sessions focused on novel platforms and agents in the treatment and prevention of diseases caused by so-called 'Superbugs' are all of interest as they cover a broad spectrum of alternate approaches and it's always good to be cognizant of new science and potential opportunities." - Janssen

"Pfizer believes that a mix of economic incentives, coupled with regulatory reforms specifically focused on antibiotics and vaccines for drug resistant strains and emerging infectious diseases, can successfully incentivize new R&D." - Pfizer

3. STRENGTHEN YOUR ANTIBIOTIC PIPELINE: **Restore antibiotic sensitivity** in multi-drug resistance infections with talks on targeting mechanisms, novel approaches in treating gram-negative infections, combination therapy, and protein based biologics as adjuncts to existing therapies.

"I'm looking forward to the section on "Strengthening the Pipeline" and hearing about the other work going on in developing beta-lactamase inhibitors." - Blueberry Therapeutics

4. ANIMAL MODELS: Join the interactive workshop hosted by the **UNT Health Science Centre** for in-depth discussions on animal models in antibiotic drug discovery. The session will cover topics on regulation, proof of concept studies, supportive data, + more!

5. REGULATION: Determine PK/PD targets for optimising dosage requirements for new for new antibacterials with regulatory recommendations from the **National Institute of Allergy & Infectious Diseases (NIAID)** in our second post conference interactive workshop.

[View full details](#)

HOW TO REGISTER

Register online at www.superbugs-usa.com

Sponsorship enquiries: Contact Alia Malick on email: amalick@smi-online.co.uk or call: +44 (0)20 7827 6168

Delegate enquiries: Contact Matthew Apps on email: mapps@smi-online.co.uk or call: +44 (0)20 7827 6184

Register online at www.superbugs-usa.com

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>